iSpecimen Inc. (NASDAQ:ISPC) Short Interest Down 99.1% in April

iSpecimen Inc. (NASDAQ:ISPC) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 51,489 shares, a decline of 99.1% from the April 15th total of 5,529,018 shares. Approximately 7.9% of the company’s stock are short sold. Based on an average daily volume of 1,959,292 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Ratings Changes

A number of equities analysts have commented on ISPC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of iSpecimen to a “sell” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

iSpecimen Price Performance

iSpecimen stock traded down $0.07 during trading hours on Monday, reaching $5.05. The stock had a trading volume of 359,243 shares, compared to its average volume of 1,770,498. iSpecimen has a 52 week low of $4.00 and a 52 week high of $127.20. The company has a market cap of $3.74 million, a price-to-earnings ratio of -0.05 and a beta of 1.75. The business’s 50 day moving average price is $6.75 and its 200-day moving average price is $13.78.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC acquired a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen as of its most recent SEC filing. Institutional investors and hedge funds own 13.62% of the company’s stock.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.